• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Analysis for the optimal condition of the autologous platelet rich plasma therapy

Research Project

Project/Area Number 18K09085
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56020:Orthopedics-related
Research InstitutionJikei University School of Medicine

Principal Investigator

Yoshida Mamoru  東京慈恵会医科大学, 医学部, 准教授 (10266702)

Co-Investigator(Kenkyū-buntansha) 舟崎 裕記  東京慈恵会医科大学, 医学部, 教授 (70199412)
丸毛 啓史  東京慈恵会医科大学, 医学部, 教授 (70199925)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
KeywordsPlatelet-rich plasma / Platelet concentration / Leukocyte concentration / Enthesopathy / Tendinopathy / Sports injury / Optimal concentration / Tendon / 多血小板血漿 / 腱症 / 血小板濃度 / 動物モデル / 腱付着部症 / 自己多血小板血漿
Outline of Final Research Achievements

In an animal model of tendinopathy, we determined if there was an optimal PRP platelet concentration. PRP at platelet concentrations of 50(P50), 75(P75), 100(P100) and 150×10000/μL(P150) or normal saline (control) was injected into the tendinopathy tendon. Activities in the P75 and P100 were significantly greater than in the P50, P150 and control. The numbers of microtears, laminations and apoptotic cells in tendons in the P75 and P100 were fewer than in the P50, P150 and control (Because of a few sample numbers, no statistical analysis was performed). These findings indicated that the optimal PRP platelet concentration was approximately a range of 75 to 100×10000/μL.

Academic Significance and Societal Importance of the Research Achievements

これまでPRP治療の至適血小板濃度は不明であり、施設間や精製キット間で濃度は統一されておらず、異なる条件下での治療成績が論じられてきた。本研究により、至適条件が明らかとなり、今後は統一した条件でPRP治療が施行されることにより、本治療法の適応と限界が明確になり、それにより、治療効果の予測が容易になることから、PRP治療か手術治療かの治療方法の選択が適切に行われ、最短時間で治療を行うことが可能になり、実臨床に多大な貢献ができる。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (6 results)

All 2021 2020

All Journal Article (3 results) (of which Peer Reviewed: 2 results,  Open Access: 2 results) Presentation (3 results)

  • [Journal Article] Optimal Platelet Concentration for The Therapeutic Effect of Autologous Neutrophil-Reduced Platelet Rich Plasma in A Rat Model of Achilles Tendinopathy2020

    • Author(s)
      M. Yoshida, H. Funasaki
    • Journal Title

      Muscle, Ligaments and tendons journal

      Volume: 10(4) Issue: 04 Pages: 612-621

    • DOI

      10.32098/mltj.04.2020.08

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] 肩・肘投球障害に対する多血小板血漿療法2020

    • Author(s)
      吉田 衛
    • Journal Title

      Monthly Book Orthopaedics

      Volume: 33(10) Pages: 136-144

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] 肘関節内側・外側上顆炎に対する多血小板血漿(PRP)治療2020

    • Author(s)
      吉田 衛、斎藤 充
    • Journal Title

      臨床雑誌“整形外科”

      Volume: 71(12) Pages: 1286-1292

    • Related Report
      2020 Annual Research Report
  • [Presentation] 腱付着部症のPRP治療における疼痛抑制と組織修復の至適血小板濃度2021

    • Author(s)
      吉田 衛、舟﨑裕記、斎藤 充
    • Organizer
      第94回日本整形外科学会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 腱症に対するPRP治療の至適血小板濃度の解析2020

    • Author(s)
      吉田 衛、舟﨑裕記、丸毛啓史
    • Organizer
      第93回日本整形外科学会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 腱症に対するPRP治療の至適血小板濃度の解析2020

    • Author(s)
      吉田 衛、舟﨑裕記、丸毛啓史
    • Organizer
      第93回日本整形外科学会学術集会
    • Related Report
      2019 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi